Quick Answer
Stoke Therapeutics, Inc. reported Total Revenue of $184.42 million for fiscal year 2025.
Stoke Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $184.42M +404.5% |
$36.55M +316.3% |
$8.78M -29.2% |
$12.40M | — | — |
| Net Income | -$6.88M +92.3% |
-$88.98M +15.0% |
-$104.70M -3.6% |
-$101.07M -17.8% |
-$85.81M -64.2% |
-$52.24M -61.6% |
| Diluted EPS | -$0.12 +92.7% |
-$1.65 +30.7% |
-$2.38 +8.5% |
-$2.60 -11.1% |
-$2.34 | — |
| Total Assets | $418.43M +54.1% |
$271.56M +18.9% |
$228.34M -10.8% |
$256.07M +7.2% |
$238.87M -19.8% |
$297.93M +30.2% |
| Cash and Equivalents | $84.22M -34.2% |
$127.98M -33.1% |
$191.44M +68.6% |
$113.56M -21.6% |
$144.90M -49.6% |
$287.31M +29.1% |
| Stockholders Equity | $352.46M +53.9% |
$229.02M +43.5% |
$159.56M -13.7% |
$184.85M -15.1% |
$217.78M -23.9% |
$286.08M +27.5% |
| R&D Expense | $137.92M +54.7% |
$89.13M +8.4% |
$82.23M +5.6% |
$77.84M +43.7% |
$54.17M +68.2% |
$32.20M +35.5% |
| Operating Income | -$20.59M +79.7% |
-$101.37M +11.7% |
-$114.77M -10.0% |
-$104.36M -21.3% |
-$86.06M -62.3% |
-$53.04M -48.7% |
| Shares Outstanding | 58.92M +9.0% |
54.03M +17.7% |
45.92M +16.4% |
39.44M +6.9% |
36.90M +0.9% |
36.58M +11.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $10.63M | +117.2% | -23.1% |
| Net Income | September 30, 2025 | -$38.35M | -45.1% | -63.3% |
| Diluted EPS | September 30, 2025 | -$0.65 | -38.3% | -62.5% |
| Total Assets | September 30, 2025 | $360.26M | +22.8% | -6.3% |
| Cash and Equivalents | September 30, 2025 | $83.39M | -44.4% | -17.8% |
| Stockholders Equity | September 30, 2025 | $308.11M | +32.7% | -8.0% |
| R&D Expense | September 30, 2025 | $37.70M | +69.8% | +45.8% |
| Operating Income | September 30, 2025 | -$43.09M | -43.6% | -57.8% |
| Shares Outstanding | September 30, 2025 | 55.12M | +4.1% | +0.7% |
- Stoke Therapeutics, Inc. reported Total Revenue of $184.42 million for fiscal year 2025.
- Stoke Therapeutics, Inc. showed an increase of +404.5% in Total Revenue compared to the prior fiscal year.
- Stoke Therapeutics, Inc. reported Net Income of -$6.88 million for fiscal year 2025.
- Stoke Therapeutics, Inc. showed an increase of +92.3% in Net Income compared to the prior fiscal year.
- Stoke Therapeutics, Inc. reported Diluted EPS of $0.12 per share (loss) for fiscal year 2025.
- Stoke Therapeutics, Inc. showed an increase of +92.7% in Diluted EPS compared to the prior fiscal year.
- Stoke Therapeutics, Inc. reported Total Assets of $418.43 million for fiscal year 2025.
- Stoke Therapeutics, Inc. showed an increase of +54.1% in Total Assets compared to the prior fiscal year.
- Stoke Therapeutics, Inc. reported Cash and Equivalents of $84.22 million for fiscal year 2025.
- Stoke Therapeutics, Inc. showed a decrease of -34.2% in Cash and Equivalents compared to the prior fiscal year.
- Stoke Therapeutics, Inc. reported Stockholders Equity of $352.46 million for fiscal year 2025.
- Stoke Therapeutics, Inc. showed an increase of +53.9% in Stockholders Equity compared to the prior fiscal year.
- Stoke Therapeutics, Inc. reported R&D Expense of $137.92 million for fiscal year 2025.
- Stoke Therapeutics, Inc. showed an increase of +54.7% in R&D Expense compared to the prior fiscal year.
- Stoke Therapeutics, Inc. reported Operating Income of -$20.59 million for fiscal year 2025.
- Stoke Therapeutics, Inc. showed an increase of +79.7% in Operating Income compared to the prior fiscal year.
- Stoke Therapeutics, Inc. reported Shares Outstanding of 58.92 million shares for fiscal year 2025.
- Stoke Therapeutics, Inc. showed an increase of +9.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: